Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records | Clinical Pharmacy and Pharmacology | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME
Key Points

Question  Is a third dose of US Food and Drug Administration–authorized COVID-19 mRNA vaccines safe?

Findings  This cohort study of electronic health record data for 47 999 individuals receiving 3-dose mRNA COVID-19 vaccines found no significant increase in the reporting of severe adverse events (ie, anaphylaxis, cerebral venous sinus thrombosis, myocarditis, and pericarditis) after the third vaccine dose compared with before vaccination and after prior doses. Significantly increased reporting was found for low-severity adverse events (ie, fatigue, lymphadenopathy, nausea, and headache).

Meaning  These findings suggest that third-dose vaccination with COVID-19 mRNA vaccines may be safe.

Abstract

Importance  Recent reports on waning of COVID-19 vaccine–induced immunity have led to the approval and rollout of additional doses and booster vaccinations. Individuals at increased risk of SARS-CoV-2 infection are receiving additional vaccine doses in addition to the regimen that was tested in clinical trials. Risks and adverse event profiles associated with additional vaccine doses are currently not well understood.

Objective  To evaluate the safety of third-dose vaccination with US Food and Drug Administration (FDA)–approved COVID-19 mRNA vaccines.

Design, Setting, and Participants  This cohort study was conducted using electronic health record (EHR) data from December 2020 to October 2021 from the multistate Mayo Clinic Enterprise. Participants included all 47 999 individuals receiving 3-dose COVID-19 mRNA vaccines within the study setting who met study inclusion criteria. Participants were divided into 2 cohorts by vaccine brand administered and served as their own control groups, with no comparison made between cohorts. Data were analyzed from September through November 2021.

Exposures  Three doses of an FDA-authorized COVID-19 mRNA vaccine, BNT162b2 or mRNA-1273.

Main Outcomes and Measures  Vaccine-associated adverse events were assessed via EHR report. Adverse event risk was quantified using the percentage of study participants who reported the adverse event within 14 days after each vaccine dose and during a 14-day control period, immediately preceding the first vaccine dose.

Results  Among 47 999 individuals who received 3-dose COVID-19 mRNA vaccines, 38 094 individuals (21 835 [57.3%] women; median [IQR] age, 67.4 [52.5-76.5] years) received BNT162b2 (79.4%) and 9905 individuals (5099 [51.5%] women; median [IQR] age, 67.7 [59.5-73.9] years) received mRNA-1273 (20.6%). Reporting of severe adverse events remained low after the third vaccine dose, with rates of pericarditis (0.01%; 95% CI, 0%-0.02%), anaphylaxis (0%; 95% CI, 0%-0.01%), myocarditis (0%; 95% CI, 0%-0.01%), and cerebral venous sinus thrombosis (no individuals) consistent with results from earlier studies. Significantly more individuals reported low-severity adverse events after the third dose compared with after the second dose, including fatigue (2360 individuals [4.92%] vs 1665 individuals [3.47%]; P < .001), lymphadenopathy (1387 individuals [2.89%] vs 995 individuals [2.07%]; P < .001), nausea (1259 individuals [2.62%] vs 979 individuals [2.04%]; P < .001), headache (1185 individuals [2.47%] vs 992 individuals [2.07%]; P < .001), arthralgia (1019 individuals [2.12%] vs 816 individuals [1.70%]; P < .001), myalgia (956 individuals [1.99%] vs 784 individuals [1.63%]; P < .001), diarrhea (817 individuals [1.70%] vs 595 individuals [1.24%]; P < .001), fever (533 individuals [1.11%] vs 391 individuals [0.81%]; P < .001), vomiting (528 individuals [1.10%] vs 385 individuals [0.80%]; P < .001), and chills (224 individuals [0.47%] vs 175 individuals [0.36%]; P = .01).

Conclusions and Relevance  This study found that although third-dose vaccination against SARS-CoV-2 infection was associated with increased reporting of low-severity adverse events, risk of severe adverse events remained comparable with risk associated with the standard 2-dose regime. These findings suggest the safety of third vaccination doses in individuals who were eligible for booster vaccination at the time of this study.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: February 22, 2022.

Published: April 14, 2022. doi:10.1001/jamanetworkopen.2022.7038

Open Access: This is an open access article distributed under the terms of the CC-BY-NC-ND License. © 2022 Niesen MJM et al. JAMA Network Open.

Corresponding Authors: Venky Soundararajan, PhD, nference, One Main St, East Arcade, Cambridge, MA 02142 (venky@nference.net); Andrew Badley, Division of Infectious Diseases, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (badley.andrew@mayo.edu).

Author Contributions: Drs Soundararajan and Badley had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Niesen, Pawlowski, and O’Horo made equal contributions.

Concept and design: Niesen, Pawlowski, O’Horo, Challener, Silvert, Lenehan, Swift, Speicher, Halamka, Venkatakrishnan, Soundararajan, Badley.

Acquisition, analysis, or interpretation of data: Niesen, Pawlowski, O’Horo, Silvert, Donadio, Virk, Gordon, Geyer, Badley.

Drafting of the manuscript: Niesen, Pawlowski, Silvert, Donadio, Venkatakrishnan, Soundararajan.

Critical revision of the manuscript for important intellectual content: Niesen, Pawlowski, O’Horo, Challener, Lenehan, Virk, Swift, Speicher, Gordon, Geyer, Halamka, Soundararajan, Badley.

Statistical analysis: Niesen, Pawlowski, Silvert, Donadio, Gordon.

Administrative, technical, or material support: O’Horo, Silvert, Gordon, Halamka, Badley.

Supervision: Niesen, O’Horo, Venkatakrishnan, Soundararajan, Badley.

Conflict of Interest Disclosures: Drs Niesen and Soundararajan reported being employees of nference, which is collaborating with biopharmaceutical companies on data science initiatives unrelated to this study. Dr Pawlowski reported receiving personal fees from nference outside the submitted work. Dr O’Horo reported receiving grants from nference and Mitre, receiving consulting fees from Bates College, and owning privately purchased stock from Doximity outside the submitted work. Dr Silvert reported receiving personal fees from nference as an employer during the conduct of the study and outside the submitted work. Dr Lenehan reported employment by nference. Dr Virk reported receiving personal fees from Moderna outside the submitted work. Dr Swift reported receiving grants from the Pfizer Healthcare Worker Exposure Response and Outcomes (HEROE) vaccine registry via Duke University outside the submitted work. Dr Badley reported receiving grants from the National Institute of Allergy and Infectious Diseases, Amfar, and Mayo Clinic; consulting fees for AbbVie, Gilead Sciences, Freedom Tunnel, PineTree Therapeutics, Primmune Therapeutics, Immunome, MarPam Pharma, Rion, Symbiosis, and Flambeau Diagnostics; and personal fees from Corvus Pharmaceuticals, Equillium, CSL Behring, Excision BioTherapeutics, ReachMD, PeerVoice, and Medscape; owning equity for scientific advisory work in Zentalis, Rion, and nference; and serving as founder and president of Splissen Therapeutics. No other disclosures were reported.

References
1.
Polack  FP , Thomas  SJ , Kitchin  N ,  et al; C4591001 Clinical Trial Group.  Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine.   N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577 PubMedGoogle ScholarCrossref
2.
Baden  LR , El Sahly  HM , Essink  B ,  et al; COVE Study Group.  Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.   N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389 PubMedGoogle ScholarCrossref
3.
Pawlowski  C , Lenehan  P , Puranik  A ,  et al.  FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system.   Med (N Y). 2021;2(8):979-992.e8. doi:10.1016/j.medj.2021.06.007 PubMedGoogle Scholar
4.
Thompson  MG , Burgess  JL , Naleway  AL ,  et al.  Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight U.S. locations, December 2020-March 2021.   MMWR Morb Mortal Wkly Rep. 2021;70(13):495-500. doi:10.15585/mmwr.mm7013e3 PubMedGoogle ScholarCrossref
5.
Puranik  A , Lenehan  PJ , Silvert  E ,  et al.  Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection.   Med (N Y). 2022;3(1):28-41.e8. doi:10.1016/j.medj.2021.12.002 PubMedGoogle Scholar
6.
Lopez Bernal  J , Andrews  N , Gower  C ,  et al.  Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant.   N Engl J Med. 2021;385(7):585-594. doi:10.1056/NEJMoa2108891 PubMedGoogle ScholarCrossref
7.
Thompson  MG , Stenehjem  E , Grannis  S ,  et al.  Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings.   N Engl J Med. 2021;385(15):1355-1371. doi:10.1056/NEJMoa2110362 PubMedGoogle ScholarCrossref
8.
Grannis  SJ , Rowley  EA , Ong  TC ,  et al; VISION Network.  Interim estimates of COVID-19 vaccine effectiveness against COVID-19-associated emergency department or urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2 B.1.617.2 (Delta) variant predominance—nine states, June-August 2021.   MMWR Morb Mortal Wkly Rep. 2021;70(37):1291-1293. doi:10.15585/mmwr.mm7037e2 PubMedGoogle ScholarCrossref
9.
Self  WH , Tenforde  MW , Rhoads  JP ,  et al; IVY Network.  Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions–United States, March-August 2021.   MMWR Morb Mortal Wkly Rep. 2021;70(38):1337-1343. doi:10.15585/mmwr.mm7038e1 PubMedGoogle ScholarCrossref
10.
Puranik  A , PJ  Lenehan , JC  O’Horo ,  et al.  Durability analysis of the highly effective BNT162b2 vaccine against COVID-19.   bioRxiv. Preprint posted online September 7, 2021. doi:10.1101/2021.09.04.21263115Google Scholar
11.
Israel  A , Merzon E, Shäffer AA,  et al.  Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort.   medRxiv. Preprint posted online August 5, 2021. doi:10.1101/2021.08.03.21261496Google Scholar
12.
Bar-On  YM , Goldberg  Y , Mandel  M ,  et al.  Protection of BNT162b2 vaccine booster against COVID-19 in Israel.   N Engl J Med. 2021;385(15):1393-1400. doi:10.1056/NEJMoa2114255 PubMedGoogle ScholarCrossref
13.
Pfizer. Pfizer and BioNTech announce phase 3 trial data showing high efficacy of a booster dose of their COVID-19 vaccine. Accessed March 8, 2022. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-phase-3-trial-data-showing
14.
Shroff  RT , Chalasani  P , Wei  R ,  et al.  Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.   Nat Med. 2021;27(11):2002-2011. doi:10.1038/s41591-021-01542-z PubMedGoogle ScholarCrossref
15.
Centers for Disease Control and Prevention. Possible Side Effects After Getting a COVID-19 Vaccine. Accessed March 8, 2022. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html
16.
Mevorach  D , Anis  E , Cedar  N ,  et al.  Myocarditis after BNT162b2 mRNA vaccine against COVID-19 in Israel.   N Engl J Med. 2021;385(23):2140-2149. doi:10.1056/NEJMoa2109730 PubMedGoogle ScholarCrossref
17.
Witberg  G , Barda  N , Hoss  S ,  et al.  Myocarditis after COVID-19 vaccination in a large health care organization.   N Engl J Med. 2021;385(23):2132-2139. doi:10.1056/NEJMoa2110737 PubMedGoogle ScholarCrossref
18.
Muir  K-L , Kallam  A , Koepsell  SA , Gundabolu  K .  Thrombotic thrombocytopenia after Ad26.COV2.S vaccination.   N Engl J Med. 2021;384(20):1964-1965. doi:10.1056/NEJMc2105869 PubMedGoogle ScholarCrossref
19.
Sadoff  J , Davis  K , Douoguih  M .  Thrombotic thrombocytopenia after Ad26.COV2.S vaccination—response from the manufacturer.   N Engl J Med. 2021;384(20):1965-1966. doi:10.1056/NEJMc2106075 PubMedGoogle ScholarCrossref
20.
Schultz  NH , Sørvoll  IH , Michelsen  AE ,  et al.  Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination.   N Engl J Med. 2021;384(22):2124-2130. doi:10.1056/NEJMoa2104882 PubMedGoogle ScholarCrossref
21.
Greinacher  A , Thiele  T , Warkentin  TE , Weisser  K , Kyrle  PA , Eichinger  S .  Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.   N Engl J Med. 2021;384(22):2092-2101. doi:10.1056/NEJMoa2104840 PubMedGoogle ScholarCrossref
22.
Scully  M , Singh  D , Lown  R ,  et al.  Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination.   N Engl J Med. 2021;384(23):2202-2211. doi:10.1056/NEJMoa2105385 PubMedGoogle ScholarCrossref
23.
McMurry  R , Lenehan  P , Awasthi  S ,  et al.  Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines.   Med (N Y). 2021;2(8):965-978.e5. doi:10.1016/j.medj.2021.06.006 PubMedGoogle Scholar
24.
Pfizer. Pfizer and BioNTech initiate rolling submission of supplemental biologics license application to U.S. FDA for booster dose of Comirnaty in individuals 16 and older. Accessed March 8, 2022. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission
25.
Mofaz  M , Ychezkel  M , Guan  G ,  et al.  Self-reported and physiological reactions to the third BNT162b2 mRNA COVID-19 (booster) vaccine dose.   bioRxiv. Preprint posted online September 22, 2021. doi:10.1101/2021.09.15.21263633Google Scholar
26.
Hause  AM , Baggs  J , Gee  J ,  et al.  Safety monitoring of an additional dose of COVID-19 vaccine United States, August 12-September 19, 2021.   MMWR Morb Mortal Wkly Rep. 2021;70(39):1379-1384. doi:10.15585/mmwr.mm7039e4 PubMedGoogle ScholarCrossref
27.
Mayo Clinic.  Institutional review board (IRB). Accessed March 9, 2022. https://www.mayo.edu/research/institutional-review-board/overview
28.
US Census Bureau.  About the topic of race. Accessed March 18, 2022. https://www.census.gov/topics/population/race/about.html
29.
US Census Bureau.  About the Hispanic population and it's origin. Accessed March 18, 2022. https://www.census.gov/topics/population/hispanic-origin/about.html
30.
Devlin  J , Chang  MW , Lee  K , and Toutanova  K. BERT: pre-training of deep bidirectional transformers for language understanding. arXiv.org. Accessed March 8, 2022. https://arxiv.org/abs/1810.04805
31.
Wagner  T , Shweta  F , Murugadoss  K ,  et al.  Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis.   Elife. 2020;9:e58227. doi:10.7554/eLife.58227 PubMedGoogle Scholar
32.
Venkatakrishnan  AJ , Pawlowski  C , Zemmour  D ,  et al.  Mapping each pre-existing condition’s association to short-term and long-term COVID-19 complications.   NPJ Digit Med. 2021;4(1):117. doi:10.1038/s41746-021-00484-7PubMedGoogle ScholarCrossref
33.
Elixhauser  A , Steiner  C , Harris  DR , Coffey  RM .  Comorbidity measures for use with administrative data.   Med Care. 1998;36(1):8-27. doi:10.1097/00005650-199801000-00004 PubMedGoogle ScholarCrossref
34.
van Walraven  C , Austin  PC , Jennings  A , Quan  H , Forster  AJ .  A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data.   Med Care. 2009;47(6):626-633. doi:10.1097/MLR.0b013e31819432e5 PubMedGoogle ScholarCrossref
35.
World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC/DDD index. Accessed March 8, 2022. https://www.whocc.no/atc_ddd_index/?code=L04A&showdescription=no
36.
Arunachalam  PS , Scott  MKD , Hagan  T ,  et al.  Systems vaccinology of the BNT162b2 mRNA vaccine in humans.   Nature. 2021;596(7872):410-416. doi:10.1038/s41586-021-03791-x PubMedGoogle ScholarCrossref
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close